Laura Alder, MD (@LauraAlderMD) ranks #8 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 39 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DeLLphi-305, ARROS-1, DESTINY-Lung04. CMS Open Payments lists $30,549 in 2025 general payments.
At a Glance
- 10 posts naming a trial in 2026
- 9 trials discussed by name
- Lung Cancer: US #8, Global #18 · 39 physicians engaged
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $30,549 in 2025 general payments.
This Month
What Laura Alder, MD has posted in the last 30 days. Updated November 10, 2026.
Pivotal #DeLLphi305 data @sands_jacob 👏, w/ a phenomenal discussion by @StephenVLiu w/ two standout quotes: ⭐️ "Innovation loses impact if it doesn't reach the patients who need it most" ⭐️ "It is not enough to know if the drugs work or how well they work, we need to know why and in whom they work to make better individualized decisions"
Who Amplifies Laura Alder, MD
Physicians who reposted Laura Alder, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #8 | #18 | 39 | 57 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Laura Alder, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · PosterDoes tarlatamab work beyond progression in SCLC? Local consolidation (SRS/SBRT) and OSSource: @LauraAlderMD on X ↗
What Colleagues Are Saying About Laura Alder, MD
2026 posts by fellow physicians that mention @LauraAlderMD, quoted word for word.
"Tarlatumab every 2 weeks indefinitely" I've pts w/ ED-SCLC in remission for yrs - on durva or even no maintenance. ▫️How long is tarla really needed? ▫️Should every pt get it? Questions only academic centers can solve! I look to @Sands_jacob @LauraAlderMD @DrShieldsMD @G_Mountzios to guide us.
Join us September 23 10am EDT as we discuss impactful studies from #WCLC26! Looking foward to hearing from thoracic oncology experts & friends: Drs. @SuyogCancer @SewantiLimaye @LauraAlderMD @g_mountzios @TejasPatilMD @ChandrakanthMv Free registration: https://t.co/odIHUm2lLY https://t.co/khZolqgkdI
At #DCLung26, @LauraAlderMD @DukeCancer reviews first-line #SCLC treatment in 2026: Which chemoimmunotherapy and maintenance regimens are preferred? Where does lurbinectedin maintenance fit in, and how might the treatment landscape evolve as tarlatamab moves into earlier lines of therapy? @SclcSMASHERS
A huge thank you to our incredible faculty @StephenVLiu @LauraAlderMD @TejasPatilMD @g_mountzios @ullas_batra Dr Chandrakanth, Dr Karan Sood for an outstanding #OncoWisdom discussion on What’s New in Lung Cancer from WCLC 2026. 🙏 402 registrations | 160 attendees Grateful for the time, expertise and honest discussion 🙂. Thank you for making it special! 🙏 And thank you for all those who attended it . I hope it was useful for all of you 🙂
Having a wonderful time at the @IASLC plenary and enjoyed checking out the @starfieldlibrary in #Korea with the amazing Dr. Laura Alder @LauraAlderMD at #WCLC26! #SCLCsisters https://t.co/bk9UUHxkLi
Trials Laura Alder, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DeLLphi-305 | 2 | #20 of 86 | Oct 24, 2026 |
| ARROS-1 | 1 | #10 of 26 | Sep 14, 2026 |
| DESTINY-Lung04 | 1 | #4 of 37 | Sep 14, 2026 |
| REZILIENT3 | 1 | #8 of 27 | Sep 14, 2026 |
| ADAURA | 1 | #20 of 41 | Sep 13, 2026 |
| PAPILLON | 1 | #6 of 26 | Sep 13, 2026 |
| SERENA-6 | 1 | #9 of 39 | Sep 6, 2026 |
| CROWN | 1 | #4 of 36 | May 21, 2026 |
| DeLLphi-304 | 1 | #6 of 23 | May 21, 2026 |
Laura Alder, MD on DeLLphi-305
Pivotal #DeLLphi305 data @sands_jacob 👏, w/ a phenomenal discussion by @StephenVLiu w/ two standout quotes: ⭐️ "Innovation loses impact if it doesn't reach the patients who need it most" ⭐️ "It is not enough to know if the drugs work or how well they work, we need to know why and in whom they work to make better individualized decisions"
📣 Changes and progress for tarlatamab in SCLC! ✅ FDA has approved REDUCED monitoring time for the first two doses: 22–24h on C1D1 and C1D8 ➡️ 6–8h. Easing this lowers a key barrier to outpatient and community administration. 🔜 Coming soon: positive overall survival results from the phase III maintenance DeLLphi-305 trial ➡️ soon moving into 1L. 📄 To help teams operationalize all of this, our recent multi-institutional perspective on tarlatamab administration and management of CRS/ICANS provides practical, real-world guidance for safe delivery. 👀 Stay tuned for outpatient-focused delivery and risk management strategies. https://t.co/zXL70ok6Gj @BZhangMD @ADesaiMD @alissajcooper @MehmetAltanMD @Annechiangmd @LaurenByersMD @Sonampuri
Laura Alder, MD on ARROS-1
Dr @alexdrilon presenting ARROS-1, Zidesamtinib for ROS1 NSCLC in 1L. - ORR 94%, PFS NR! #WCLC26 ‼️measurable CNS Mets n=10, IC-ORR 100% - Tox similar to other ROS1 TKIs. ⭐️Another efficacious option joins Taletrectinib! https://t.co/xgsJ0gw1mN
Laura Alder, MD on DESTINY-Lung04
Dr @JuliaRotow with terrific presentation of DESTINY-Lung04 #WCLC26. ORR 70% vs 44.5%, improved PFS. ‼️No significant OS benefit ; notably, 48% of chemo arm did receive subsequent HER2 directed treatment 🚨ILD any grade 20.8% (78.7% G 1/2) ⭐️Zongertinib my choice for 1L treatment in HER2 TKD alterations
Laura Alder, MD on REZILIENT3
Dr Daniel Tan presents REZILIENT 3 at #WCLC26, Zipalertinib offers oral TKI option (+chemo) for EGFR exon 20ins. Impressive benefit in those with CNS mets! ORR 65% vs 40.3%. Favorable trend for OS benefit (64% crossover). 80% Grade 3 or higher TRAEs largely cytopenias. https://t.co/80JBCajxkS
Laura Alder, MD on ADAURA
Dr @DrRoyHerbst presenting 8 year (!) data on ADAURA. #WCLC26 Highlights are ongoing survival benefit, well after stopping Osimertinib, including stage III! Benefit of surgery likely powerful here, future directions include MRD testing to help direct treatment decisions, and incorporation of neoadjuvant treatment
Laura Alder, MD on PAPILLON
Phenomenal presentation by @chulkimMD on PAPILLON OS @ #WCLC26! ⭐️OS impressive improvement, 34.3 mo, (notable 76% crossover), toxicities remain challenging. Thankfully a growing field, offering this and additional options to our patients. https://t.co/eJ4eELxBR7
Laura Alder, MD on SERENA-6
SERENA-6 showed that ctDNA-guided switching before radiographic progression can extend PFS in breast cancer. Worth remembering that lung cancer already ran a similar study: -APPLE (EORTC LCG-1613) monitored plasma T790M on gefitinib and switched to osimertinib at molecular https://t.co/cNjAuJtN9s
Laura Alder, MD on CROWN
🧵 CROWN 7-Year Update: Lorlatinib in 1L ALK+ NSCLC: the longest PFS ever reported in advanced NSCLC keeps getting longer!!! #ASCO26 🫁 Abstracts! Presenter: @TonyMok9 Key takeaways: 👇 @ALKPositiveinc 1) 1/ 📈 Median PFS STILL not reached at 7 years. • 7-yr PFS rate: 55% https://t.co/SoInsv7wwc
Laura Alder, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Excited to see the full presentation #ASCO26 by @LaurenByersMD on ABBV-706, a SEZ6 ADC with promising activity in relapsed/refractory #SCLC! 📊 Key results: • ORR 82% in 2L pts (1.8 mg/kg) ‼️ • mOS 14.3 mo in 2L monotherapy • 15-mo OS rate: 50% • Combo w/ budigalimab (anti-PD-1): ORR 55%, mPFS 8.1 mo, no new safety signals ⭐️No treatment-related deaths. No pneumonitis with combo! (small n) An ADC target in SCLC worth watching !! 👀 @drshieldsmd @ASCO #lcsm @alissajcooper
Excited to be selected as an #ASCO26 Featured Voice, along with esteemed colleagues and friends!! It's going to be an incredible meeting! From practice-changing lung cancer trials to landmark plenary sessions across oncology, there is SO much to cover. 🫁 Can't wait to share the science, the data, and what it means for our patients. Follow along! 🧵👇 @lungoncdoc @ASCO #lcsm graphics: @ADesaiMD, @Latinamd
🚨 Who's ready for SCLC updates at #WCLC26?! 🫁 1️⃣ Dr J͟o͟n͟a͟t͟h͟a͟n͟ ͟G͟o͟l͟d͟m͟a͟n͟ presents DeLLphi-309: randomized Phase 2 of tarlatamab extended-interval dosing in SCLC. 💉 Less-frequent dosing could ease treatment burden and "time toxicity," keeping efficacy while giving patients back more days off therapy. 2️⃣ Dr A͟l͟b͟e͟r͟t͟o͟ ͟C͟h͟i͟a͟p͟p͟o͟r͟i͟ on LB2102: a dnTGFBR2-armored, DLL3-targeted autologous CAR-T in relapsed/refractory SCLC & LCNEC. 🧬 Brings the promise of durable, one-time cell therapy,and the hope of long-term benefit to a disease that relapses fast. 3️⃣ Dr Z͟h͟u͟x͟i͟n͟g͟ ͟X͟i͟a͟ reveals how epigenetic dysregulation drives E2F1-mediated neuroendocrine transformation in EGFR-mutant lung adenocarcinoma. 🔬 Transformed patients face a poor prognosis with few options, this mechanistic insight addresses a critical unmet need and points toward new targets. 🎙 Discussant: Dr H͟i͟r͟o͟a͟k͟i͟ ͟A͟k͟a͟m͟a͟t͟s͟u͟ @AkamatsuHiroaki | Q&A 5:27–6:00 PM Session OA05 — "From Discovery to Practice in SCLC" | Sun Sept 13, 4:45 PM KST, Room 103 @SclcSMASHERS @EGFRResisters @OncoAlert @IASLC @LUNGevity @LungCancerEu @Lung_Cancers
DLL3-🛡️CAR-T for SCLC is here! #ASCO26 | LB2102 Phase 1 (n=20) — Dr. Zhonglin Hao et al. ✅ No DLTs · No deaths 📊 ORR 27% · DCR 91% ⏳ Median DOR 208 days ! 📈 Higher CAR-T expansion → better response Dose optimization could unlock even more activity. #LCSM @sands_jacob @BalazsHalmosMD @BenCreelan
Another ADC joins the SCLC armamentarium! Tam-Peli with huge OS, PFS and intracranial benefit over topotecan!! #WCLC26. Wonderful to have more options. Optimal choice of agent(s), sequencing, and resistance are areas of future investigation. @IASLC @SclcSMASHERS @drshieldsmd https://t.co/78orgwEKGA
Industry Payments
CMS Open Payments · 2025 general payments
$30,549 across 29 payments